Chronic idiopathic myelofibrosis (CIMF) resulting from a unique 3;9 translocation disrupting the janus kinase 2 (JAK2) gene

Experimental and Molecular Pathology

Volumn 81, Issue 3, 2006, Pages 217-223

  Mark, Hon Fong L ^a   Sotomayor, Edgar A ^b   Nelson, Marilu ^c   Chaves, Fernando ^a   Sanger, Warren G ^c   Kaleem, Zahid ^b   Caughron, Samuel K ^b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RIBOPHORIN I;

ADULT; ANAMNESIS; ARTICLE; BLOOD; BONE MARROW BIOPSY; CASE REPORT; CHROMOSOME REARRANGEMENT; CYTOGENETICS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE DISRUPTION; GENE TRANSLOCATION; HUMAN; HUMAN TISSUE; JANUS KINASE 2 GENE; LEUKEMOGENESIS; MALE; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER;

CHROMOSOME BANDING; CHROMOSOMES, HUMAN, PAIR 3; CHROMOSOMES, HUMAN, PAIR 9; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; JANUS KINASE 2; MALE; METAPHASE; MIDDLE AGED; MYELOFIBROSIS; TRANSLOCATION, GENETIC;

EID: 33750497611     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2006.07.004     Document Type: Article

References (36)

1. Baxter E.J., Scottt L.M., Campbell P.J., East C., Fourouclas N., Swanton S., Vassiliou G.S., Bench A.J., Boyd E.M., Curtin N., Scott M.A., Erber W.N., and Green A.R. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365 (2005) 1054-1061
2. Heim S., and Mitelman F. Cancer Cytogenetics. 2nd Ed. (1995), Wiley-Liss, NewYork
3. http://www.infobiogen.fr/services/chromcancer/Genes/JAK98.html.
4. Jaffe E.S., Harris N.L., Stein H., and Vardiman J.W. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues (2001), IARC Press, Lyon
5. James C., Ugo V., Le Couedic J.P., Staerk J., Delhommeau F., Lacout C., Garcon L., Raslova H., Berger R., Bennaceur-Griscelli A., Villeval J.L., Constantinescu S.N., Casadevall N., and Vainchenker W. A unique clonal JAK2 mutation leading to constitutive signaling causes polycytthaeemia vera. Nature 434 (2005) 1144-1148
6. Jones A.V., Kreil S., Zoi K., Waghorn K., Curtis C., Zhang L., Score J., Seear R., Chase A.J., Grand F.H., White H., Zoi C., Loukopoulos D., Terpos E., Vervessou E.C., Schultheis B., Emig M., Ernst T., Lengfelder E., Hehlmann R., Hochhaus A., Oscier D., Silver R.T., Reiter A., and Cross N.C. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 106 (2005) 2162-2168
7. Joos S., Kupper M., Ohl S., von Bonin F., Mechtersheimer G., Bentz M., Marynen P., Moller P., Pfreundschuh M., Trumper L., and Lichter P. Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells. Cancer Res. 60 (2000) 549-552
8. Joos S., Granzow M., Holtgreve-Grez H., Siebert R., Harder L., Martin-Subero J.I., Wolf J., Adamowicz M., Barth T.F., Lichter P., and Jauch A. Hodgkin's lymphoma cell lines are characterized by frequent aberrations on chromosomes 2p and 9p, including REL and JAK2. Int. J. Cancer 103 (2003) 489-495
9. Kralovics R., Passamonti F., Buser A.S., et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 352 (2005) 1779-1790
10. Levine R.L., Wadleigh M., Cools J., et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7 (2005) 387-397
11. Mahon F.X. JAK the trigger. Oncogene 24 (2005) 7125-7126
12. Mark H.F.L. Bone marrow cytogenetics and hematologic malignancies. In: Kaplan B.J., and Dale K.S. (Eds). The Cytogenetic Symposia. Association of Cytogenetic Technologists (1994), Burbank, California 1-7 Chapter 8
13. Mark H.F.L. Medical Cytogenetics (2000), Marcel Dekker, Inc., New York
14. Mark H.F.L. Fluorescent in situ hybridization (FISH): applications for clinical cytogenetics laboratories. In: Mark H.F.L. (Ed). Medical Cytogenetics (2000), Marcel Dekker, Inc., New York 553-578
15. Mark H.F.L. FISH as an adjunct to conventional cytogenetics: analysis of metaphase and interphase cells. In: Malhotra S. (Ed). Advances in Structural Biology vol. 6 (2000), Jai Press, Inc., Stamford, CT 1-39
16. Mark H.F.L. Cytogenetic aberrations in hematologic malignancies. In: Dunn B., Mouchrani P., and Keagle M. (Eds). The Cytogenetic Symposia. Association of Cytogenetic Technologists (2005), Burbank, California 1-8 Chapter 13
17. Mark H.F.L., and Chow B. Localization of the gene encoding the secretin receptor on human chromosone 2q by fluorescent in situ hybridization and chromosome morphometry. Genomics 29 (1995) 817-818
18. Mark H.F.L., Sikov W., Safran H., King T.C., and Griffith R.C. Fluorescent in situ hybridization for assessing the proportion of cells with trisomy 4 in a patient with acute non-lymphoblastic leukemia. Ann. Clin. Lab. Sci. 25 (1995) 330-335
19. Mark H.F.L., Jenkins R., and Miller W. Current applications of molecular cytogenetic technologies. Ann. Clin. Lab Sci. 27 (1996) 47-56
20. Mark H.F.L., Mark Y., Sotomayor E., and Sambandam S. A patient with myelodysplastic syndrome studied by GTG-banding and fluorescent in situ hybridization. Cytobios 94 (1998) 121-128
21. Mark H.F.L., Pryzgoda J., and Sikov W. Fluorescent in situ hybridization for identifying cytogenetic abnormalities in inadequate and suboptimal specimens. Pathobiology 66 (1998) 216-220
22. Mark H.F.L., Rehan J., Mark S., Santoro K., and Zolnierz K. FISH analysis of single-cell trisomies for determination of clonality. Cancer Genet. Cytogenet. 102 (1998) 1-5
23. Mark H.F.L., Bai H., Sotomayor E., Mark S., Zolnierz K., Airall E., and Sigman M. A variant Klinefelter syndrome patient with a XXY/XX/XY karyotype studied by GTG-banding and fluorescent in situ hybridization (FISH). Exp. Mol. Pathol. 67 (1999) 50-56
24. Mark H.F.L., Gray Y., Khorsand J., Mark Y., and Sikov W. A multimodal approach in diagnosing patients with hematopoietic disorders. Cancer Genet. Cytogenet. 109 (1999) 14-20
25. Mark H.F.L., Gray Y., Sotomayor E., and Joseph P. Trisomy 9 in secondary AML detected by fluorescent in situ hybridization (FISH). Pathobiology 67 (1999) 111-114
26. Mark H.F.L., Bai H., Sotomayor E., Mark S., and Rintels P. Hypotetraploidy in a patient with small cell carcinoma. Exp. Mol. Pathol. 68 (2000) 70-76
27. Mark, H.F.L., Sokolic, R., Mark, Y., 2006. Conventional cytogenetics and FISH in the detection of BCR/ABL fusion in chronic myeloid leukemia (CML). Exp. Mol. Pathol. 81, 1--7.
28. Miranda R.N., Mark H.F.L., and Medeiros L.J. Fluorescent in situ hybridization in routinely processed bone marrow aspirate clot and core biopsy sections. Am. J. Pathol. 145 (1994) 1-6
29. Papenhausen P.R., Griffin S., and Tepperberg J. Oncogene amplification in transforming myelodysplasia. Exp. Mol. Pathol. 79 (2005) 168-175
30. Scott L.M., Campbell P.J., Baxter J., et al. The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders. Blood 106 (2005) 2920-2921
31. In: Shaffer L., and Tommerup N. (Eds). ISCN (2005): An International System for Human Cytogenetic Nomenclature (2005), S. Karger, Basel
32. Sokolic R.A., Ferguson W., and Mark H.F.L. Discordant detection of monosomy 7 by GTG-banding and FISH in a patient with Shwachman-Diamond syndrome. Cancer Genet. Cytogenet. 115 (1999) 106-113
33. Steensma D.P., Dewald G.W., Lasho T.L., Powell H.L., McClure R.F., Levine R.L., Gilliland D.G., and Tefferi A. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood 106 (2005) 1207-1209
34. Strehl S. JAK2 (janus kinase 2). Atlas Genet Cytogenet Oncol Haematol (2005) (September)
35. Verma A., Kambhampati S., Parmar S., and Platanias L.C. Jak family of kinases in cancer. Cancer Metastasis Rev. 22 (2003) 423-434
36. Zhao R., Xing S., Li Z., Fu X., Li Q., Krantz S.B., and Zhao Z.J. Identification of an acquired JAK2 mutation in polycythemia vera. J. Biol. Chem. 280 (2005) 22788-22792